{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:23:41Z","timestamp":1787775821521,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Transplantation of human umbilical cord blood cells (hUCB) may enhance neuroprotection, and thus, the intravenous (IV) infusion of hUCB in patients with acute ischemic stroke (AIS) is being tested for its safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We conducted a 12-month, open-label, and single-center, phase I trial of hUCB treatment in AIS patients at the age of 45\u201380 years, with magnetic resonance imaging evidence of acute infarction in the internal carotid artery supplied territory and the National Institute of Health Stroke Scale (NIHSS) score between 6 and 18. Eligible participants received a single-dose IV infusion of hUCB followed by the two doses of mannitol infusion within 9 days after the onset of stroke symptoms. The primary endpoint was the incidence of adverse events (AEs) and the secondary endpoints were the changes in NIHSS, Barthel index (BI), and Berg Balance Scale (BBS) scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Six patients (Male: Female = 3: 3) were enrolled with a mean age at 65.8 years. A total of 40 AEs occurred in six participants during this study, which included nine serious adverse events. Only transient erythema multiforme and hematuria were probably and possibly related to hUCB infusion, respectively. The mean NIHSS score was 11.5 at baseline and it significantly improved at 1, 3, 6, 9, and 12 months after treatment (mean change from baseline: \u22124.0, \u22125.3, \u22126.8, \u22127.0, and \u22127.3). The mean BI score was 22.5 at baseline and it significantly increased at 3 and 6 months after treatment (mean change from baseline: 26.7 and 42.5, respectively). The BBS score increased numerically but did not reach statistical significance. The changes in cytokine levels and spleen size were unremarkable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The IV hUCB was safe and well tolerated in AIS patients, and the preliminary efficacy results demonstrated its therapeutic potential, supporting the conduct of a randomized, placebo controlled, phase II clinical trial in future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_249_24","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T01:00:25Z","timestamp":1746838825000},"page":"321-327","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic human umbilical cord blood for acute ischemic stroke: Phase I clinical trial"],"prefix":"10.4103","volume":"37","author":[{"given":"Raymond Y.","family":"Lo","sequence":"first","affiliation":[{"name":"Department of Neurology, Taitung St. Mary\u2019s Hospital, Taitung, Taiwan"},{"name":"Department of Neurology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"Department of Biochemistry and Molecular Medicine, National Dong Hwa University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuncin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taitung St. Mary\u2019s Hospital, Taitung, Taiwan"},{"name":"College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Cin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Hung","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Ko","sequence":"additional","affiliation":[{"name":"StemCyte Taiwan Co., Ltd., Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"StemCyte Taiwan Co., Ltd., Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chin","family":"Su","sequence":"additional","affiliation":[{"name":"StemCyte Taiwan Co., Ltd., Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"StemCyte Taiwan Co., Ltd., Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas C.","family":"Wang","sequence":"additional","affiliation":[{"name":"StemCyte Inc., CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Zong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"R1-20250701","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF03033155","article-title":"Human umbilical cord blood (HUCB) cells for central nervous system repair","volume":"5","author":"Newman","year":"2003","journal-title":"Neurotox Res"},{"key":"R2-20250701","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/scd.2005.14.595","article-title":"Anti-inflammatory effects of human cord blood cells in a rat model of stroke","volume":"14","author":"Vendrame","year":"2005","journal-title":"Stem Cells Dev"},{"key":"R3-20250701","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.expneurol.2006.03.017","article-title":"Cord blood rescues stroke-induced changes in splenocyte phenotype and function","volume":"199","author":"Vendrame","year":"2006","journal-title":"Exp Neurol"},{"key":"R4-20250701","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/sctm.18-0008","article-title":"Allogeneic umbilical cord blood infusion for adults with ischemic stroke:Clinical outcomes from a phase I safety study","volume":"7","author":"Laskowitz","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"R5-20250701","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/rme.10.97","article-title":"Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke","volume":"6","author":"Battistella","year":"2011","journal-title":"Regen Med"},{"key":"R6-20250701","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3727\/096368916X690971","article-title":"Breaking the blood-brain barrier with mannitol to aid stem cell therapeutics in the chronic stroke brain","volume":"25","author":"Tajiri","year":"2016","journal-title":"Cell Transplant"},{"key":"R7-20250701","doi-asserted-by":"crossref","first-page":"594672","DOI":"10.3389\/fneur.2020.594672","article-title":"Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery","volume":"11","author":"Bernardo-Castro","year":"2020","journal-title":"Front Neurol"},{"key":"R8-20250701","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1161\/STROKEAHA.115.008861","article-title":"Assessment of blood-brain barrier disruption in stroke","volume":"46","author":"Kassner","year":"2015","journal-title":"Stroke"},{"key":"R9-20250701","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13770-020-00293-1","article-title":"Mannitol augments the effects of systemical stem cell transplantation without increasing cell migration in a stroke animal model","volume":"17","author":"Lee","year":"2020","journal-title":"Tissue Eng Regen Med"},{"key":"R10-20250701","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/BS9.0000000000000110","article-title":"Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Shen","year":"2022","journal-title":"Blood Sci"},{"key":"R11-20250701","doi-asserted-by":"crossref","first-page":"9636897211067447","DOI":"10.1177\/09636897211067447","article-title":"Complete restoration of motor function in acute cerebral stroke treated with allogeneic human umbilical cord blood monocytes:Preliminary results of a phase I clinical trial","volume":"30","author":"Lee","year":"2021","journal-title":"Cell Transplant"},{"key":"R12-20250701","doi-asserted-by":"crossref","first-page":"9636897221083863","DOI":"10.1177\/09636897221083863","article-title":"Final results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS):A phase II, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial","volume":"31","author":"de Celis-Ruiz","year":"2022","journal-title":"Cell Transplant"},{"key":"R13-20250701","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1474-4422(17)30046-7","article-title":"Safety and efficacy of Multipotent adult progenitor cells in acute ischaemic stroke (MASTERS):A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"16","author":"Hess","year":"2017","journal-title":"Lancet Neurol"},{"key":"R14-20250701","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2016.2.FOCUS15637","article-title":"Neurorestoration after stroke","volume":"40","author":"Azad","year":"2016","journal-title":"Neurosurg Focus"},{"key":"R15-20250701","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3171\/2018.5.JNS173147","article-title":"Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623):A phase 1\/2a study","volume":"131","author":"Steinberg","year":"2019","journal-title":"J Neurosurg"},{"key":"R16-20250701","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11684-014-0371-x","article-title":"Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke:Perspectives and challenges","volume":"9","author":"Li","year":"2015","journal-title":"Front Med"},{"key":"R17-20250701","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/asheducation-2018.1.228","article-title":"Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation","volume":"2018","author":"Hamilton","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R18-20250701","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1503\/cmaj.051322","article-title":"Granulocyte colony-stimulating factor for acute ischemic stroke:A randomized controlled trial","volume":"174","author":"Shyu","year":"2006","journal-title":"CMAJ"},{"key":"R19-20250701","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/09593985.2016.1138347","article-title":"Responsiveness of the berg balance scale in patients early after stroke","volume":"32","author":"Saso","year":"2016","journal-title":"Physiother Theory Pract"},{"key":"R20-20250701","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12974-019-1400-0","article-title":"The spleen may be an important target of stem cell therapy for stroke","volume":"16","author":"Wang","year":"2019","journal-title":"J Neuroinflammation"},{"key":"R21-20250701","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0271678X15607880","article-title":"Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage","volume":"36","author":"Vahidy","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"key":"R22-20250701","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.08.012","article-title":"The volume of the spleen and its correlates after acute stroke","volume":"25","author":"Chiu","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_249_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:43:19Z","timestamp":1787773399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_249_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_249_24","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"2024-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}